Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Polo-like kinase 1 is a potential therapeutic target in human melanoma.

Jalili A, Moser A, Pashenkov M, Wagner C, Pathria G, Borgdorff V, Gschaider M, Stingl G, Ramaswamy S, Wagner SN.

J Invest Dermatol. 2011 Sep;131(9):1886-95. doi: 10.1038/jid.2011.136. Epub 2011 Jun 9.

2.

Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.

Schmit TL, Zhong W, Setaluri V, Spiegelman VS, Ahmad N.

J Invest Dermatol. 2009 Dec;129(12):2843-53. doi: 10.1038/jid.2009.172. Epub 2009 Jun 25.

3.

Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways.

Pathria G, Wagner C, Wagner SN.

J Invest Dermatol. 2012 Dec;132(12):2780-90. doi: 10.1038/jid.2012.233. Epub 2012 Jul 26.

4.

Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.

Jiang CC, Lucas K, Avery-Kiejda KA, Wade M, deBock CE, Thorne RF, Allen J, Hersey P, Zhang XD.

Cancer Res. 2008 Aug 15;68(16):6708-17. doi: 10.1158/0008-5472.CAN-08-0349.

5.

RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.

Yu C, Zhang X, Sun G, Guo X, Li H, You Y, Jacobs JL, Gardner K, Yuan D, Xu Z, Du Q, Dai C, Qian Z, Jiang K, Zhu Y, Li QQ, Miao Y.

J Cell Mol Med. 2008 Dec;12(6A):2334-49. doi: 10.1111/j.1582-4934.2008.00257.x. Epub 2008 Feb 5.

6.

Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.

Gomes CP, Gomes-da-Silva LC, Ramalho JS, de Lima MC, Simões S, Moreira JN.

Curr Gene Ther. 2013 Jun 1;13(3):189-201.

PMID:
23531193
7.

Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1.

Seo YJ, Kim BS, Chun SY, Park YK, Kang KS, Kwon TG.

J Korean Med Sci. 2011 Nov;26(11):1489-94. doi: 10.3346/jkms.2011.26.11.1489. Epub 2011 Oct 27.

8.

Targeted knockdown of polo-like kinase 1 alters metabolic regulation in melanoma.

Gutteridge RE, Singh CK, Ndiaye MA, Ahmad N.

Cancer Lett. 2017 May 28;394:13-21. doi: 10.1016/j.canlet.2017.02.013. Epub 2017 Feb 22.

PMID:
28235541
9.

Genomewide RNAi screen identifies protein kinase Cb and new members of mitogen-activated protein kinase pathway as regulators of melanoma cell growth and metastasis.

Schönherr M, Bhattacharya A, Kottek T, Szymczak S, Köberle M, Wickenhauser C, Siebolts U, Saalbach A, Koczan D, Magin TM, Simon JC, Kunz M.

Pigment Cell Melanoma Res. 2014 May;27(3):418-30. doi: 10.1111/pcmr.12216. Epub 2014 Jan 31.

PMID:
24406113
10.

The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells.

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA.

BMC Cancer. 2008 Sep 30;8:276. doi: 10.1186/1471-2407-8-276.

11.

Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.

Deng H, Jiang Q, Yang Y, Zhang S, Ma Y, Xie G, Chen X, Qian Z, Wen Y, Li J, Yang J, Chen L, Zhao X, Wei Y.

Cancer Biol Ther. 2011 Feb 15;11(4):401-9. Epub 2011 Feb 15.

PMID:
21150280
12.

Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.

Schwermer M, Dreesmann S, Eggert A, Althoff K, Steenpass L, Schramm A, Schulte JH, Temming P.

Clin Exp Ophthalmol. 2017 Apr;45(3):288-296. doi: 10.1111/ceo.12838. Epub 2016 Nov 10.

PMID:
27647547
13.

Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.

Bu Y, Yang Z, Li Q, Song F.

Oncology. 2008;74(3-4):198-206. doi: 10.1159/000151367. Epub 2008 Aug 20.

PMID:
18714168
14.

Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.

Zhang R, Shi H, Ren F, Liu H, Zhang M, Deng Y, Li X.

Oncol Rep. 2015 Mar;33(3):1235-42. doi: 10.3892/or.2015.3723. Epub 2015 Jan 15.

PMID:
25592872
15.

Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.

Posch C, Cholewa BD, Vujic I, Sanlorenzo M, Ma J, Kim ST, Kleffel S, Schatton T, Rappersberger K, Gutteridge R, Ahmad N, Ortiz/Urda S.

J Invest Dermatol. 2015 Oct;135(10):2475-2483. doi: 10.1038/jid.2015.198. Epub 2015 May 27.

16.

siRNA targeting PLK-1 induces apoptosis of synoviocytes in rheumatoid arthritis.

Wada M, Kawahito Y, Kimura S, Kohno M, Ishino H, Kimura M, Omoto A, Yamamoto A, Hamaguchi M, Tsubouchi Y, Tokunaga D, Hojo T, Ashihara E, Maekawa T, Yoshikawa T.

Biochem Biophys Res Commun. 2007 Jun 1;357(2):353-9. Epub 2007 Apr 9.

PMID:
17434144
18.

Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.

Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, Yokota A, Segawa H, Toda Y, Kageyama S, Yoshiki T, Okada Y, Maekawa T.

J Clin Invest. 2005 Apr;115(4):978-85. Epub 2005 Mar 10.

19.

Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner.

Ree AH, Bratland A, Solberg Landsverk K, Fodstad O.

Anticancer Res. 2004 Mar-Apr;24(2B):555-62.

20.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P.

Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17.

Supplemental Content

Support Center